Myelodysplastic syndrome

Testing for prognosis and risk stratification

Our approach to myelodysplastic syndrome (MDS) testing utilizes comprehensive fluorescence in situ hybridization (FISH) panels to detect for genetic biomarkers associated with disease severity, progression, and treatment response. Because all MDS testing at Mayo Clinic Laboratories is performed at one facility, the need for splitting patient samples or submitting multiple samples is diminished, while continuity of care is enhanced.

Myelodysplastic syndrome Test menu

Myelodysplastic syndrome

For patients affected by MDS, the need for ongoing testing is of vital importance for disease management and is recommended by both the National Comprehensive Cancer Network (NCCN) and the World Health Organization (WHO). Because treatment decisions are often based on illness severity, advanced testing can aid in diagnosis, disease monitoring, and treatment management in patients with MDS.

Key testing

Additional testing



Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.